| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate | 884 | GlobeNewswire (Europe) | Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with
our AI-Immunology platformEVX-04 is a therapeutic cancer vaccine candidate... ► Artikel lesen | |
| Mo | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Fr | Evaxion A/S to announce business update and third quarter 2025 financial results on November 6, 2025 | 444 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will provide a business update... ► Artikel lesen | |
| Do | Evaxion raises $7.2 million, extending cash runway to second half of 2027 | 243 | GlobeNewswire (Europe) | Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross inflow of cash of $14.7 million since the end of the second quarter... ► Artikel lesen | |
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 27.10. | Evaxion names Helen Tayton-Martin as new CEO | 3 | Seeking Alpha | ||
| 27.10. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.10. | Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer | 266 | GlobeNewswire (Europe) | Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30... ► Artikel lesen | |
| 20.10. | H.C. Wainwright reiterates Buy rating on Evaxion Biotech stock with $16 target | 2 | Investing.com | ||
| 17.10. | ESMO: Evaxion hopes cancer vax data attracts partner after cash crunch forces smaller ph. 2 trial | 3 | FierceBiotech | ||
| 17.10. | Evaxion A/S erhöht Grundkapital durch ADS-Verkäufe und Ausübung von Optionsscheinen | 4 | Investing.com Deutsch | ||
| 17.10. | Evaxion reports 75% response rate in melanoma vaccine trial | 3 | Investing.com | ||
| 17.10. | Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 | 305 | GlobeNewswire (Europe) | 75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed... ► Artikel lesen | |
| 14.10. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 13.10. | Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 | 345 | GlobeNewswire (Europe) | Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing... ► Artikel lesen | |
| 08.10. | Evaxion expands AI-Immunology platform with automated vaccine design module | 292 | GlobeNewswire (Europe) | New platform module automates previous manual vaccine design processes, improving quality and dramatically reducing time and resource requirementsAI-Immunology, already superior in vaccine target discovery... ► Artikel lesen | |
| 06.10. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.10. | Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting | 359 | GlobeNewswire (Europe) | New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions... ► Artikel lesen | |
| 25.09. | MSD pays up to nearly $600m for Evaxion's mystery vaccine candidate | 32 | Pharmaceutical Technology | ||
| 25.09. | Evaxion Stock Jumps 27% On Merck Out-Licensing Deal | 20 | RTTNews | ||
| 25.09. | Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co. | 397 | AFX News | KENILWORTH (NJ) (dpa-AFX) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 91,00 | -0,27 % | Millionen für BioNTech und Evotec! Doch Medikamentenentwicklung kostet! Deshalb auf den Übernahmekandidaten NetraMark Aktie setzen!? | Nächste Erfolgsmeldung für NetraMark. Die KI des Unternehmens hat das nächste Biopharmaunternehmen überzeugt und wird immer mehr zum Übernahmekandidaten. Der neue Kunde will mit NetraAI seine klinische... ► Artikel lesen | |
| EVOTEC | 5,818 | -17,89 % | EQS-News: Evotec SE: Bekanntgabe der Ergebnisse für die ersten neun Monate 2025 am 05. November 2025 | EQS-News: Evotec SE
/ Schlagwort(e): 9-Monatszahlen
Evotec SE: Bekanntgabe der Ergebnisse für die ersten neun Monate 2025 am 05. November 2025
29.10.2025 / 09:45 CET/CEST
Für... ► Artikel lesen | |
| QIAGEN | 38,220 | -3,67 % | QIAGEN zahlt rund 500 Mio. USD durch synthetischen Aktienrückkauf an seine Aktionäre zurück | Venlo (NL) (www.anleihencheck.de) - QIAGEN zahlt rund 500 Mio. USD durch synthetischen Aktienrückkauf an seine Aktionäre zurück - AnleihenewsQIAGEN N.V. (ISIN NL0015002CX3/ WKN A40ZZU) gibt Pläne bekannt... ► Artikel lesen | |
| CUREVAC | 4,570 | -0,91 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| AMGEN | 275,45 | +6,43 % | AMGEN wird noch optimistischer | Das letzte Quartal velrief überraschend gut und so schaut AMGEN noch optimistischer auf das ganze Jahr, als es vorher schon der Fall war. Der Biotech-Konzern aus den USA teilte gerade mit, dass der... ► Artikel lesen | |
| NOVAVAX | 6,813 | +4,21 % | Novavax Completes Marketing Authorization Transfers For Nuvaxovid To Sanofi | PARIS (dpa-AFX) - Novavax (NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid to Sanofi (SNY), enabling Sanofi to take full responsibility... ► Artikel lesen | |
| STRYKER | 308,90 | -2,22 % | Stryker Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed earnings for its third quarter that Increased from the same period last year and beat the Street estimates.The company's earnings came in... ► Artikel lesen | |
| BIOGEN | 132,30 | +1,65 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,600 | +0,81 % | Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,231 | -0,89 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,140 | +2,80 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,83 | -0,01 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| PRAXIS PRECISION MEDICINES | 163,89 | -4,63 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| MODERNA | 20,595 | -3,45 % | Moderna: Neues zur Tumor-Therapie mRNA-2808 | Moderna hat den ersten Patient in einer klinischen Phase-1/2-Studie mit dem Wirkstoffkandidaten mRNA-2808 behandelt. Der mRNA-basierte T-Cell-Engager wird nach Angaben des US-Biotechunternehmens vom... ► Artikel lesen |